Korean team finds new mechanism to boost drug delivery into advanced liver cancer
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Various compounds targeting diverse oncogenic signaling pathways have been developed for HCC patients, but clinical outcomes so far have been unsatisfactory.
A research team of gastroenterology professors Kim Do-young and Park Jun-yong and researcher Cho Kyungjoo at Severance Hospital announced the results of an animal model study that could dramatically increase the efficiency of drug delivery by regulating the expression of the signaling protein YAP/TAZ in advanced liver cancer, the hospital said on Monday.
The team developed two murine models that mimic the pathological characteristics in HCC using hydrodynamics-based transfection (HT) methods and compared the models to observe drug penetration based on YAP/TAZ expression. Activation of tumor stroma was observed in HCC with a high YAP/TAZ activity, which impaired drug penetration.
In a model with low YAP/TAZ expression with low stromal activation, the effect of drug delivery was similar to that of the tissue surrounding the tumor as time passed. However, in the other model with high YAP/TAZ expression, the effect of drug penetration in the cancer tissue was about 4 times lower than that of the tissue surrounding the tumor over time.
Tumor organoids were treated with a drug, and distributions of the drug in the organoids were assessed using fluorescence microscopy. Consistent with the findings in the in vivo models of HCC, MCHOs with activated YAP/TAZ signaling showed stromal activation and impaired drug penetration. Inhibition of YAP/TAZ transcriptional activity in HCC cells significantly increased drug penetration into the MCHO.
The research findings were published in the latest issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).
Drug development for liver cancer has been slow compared to other cancer types because liver function must be considered in pharmacological action in addition to drug efficacy and adverse reactions. According to Korean Liver Cancer Association, about 80 percent of all liver cancer patients have various underlying diseases, including cirrhosis. Activation of tumor stroma is observed in HCC with cirrhosis where drug delivery through blood vessels is not satisfactory.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Seoul may go back to tightened mitigation as hospitals run out of beds for critically ill - Pulse by Maeil Business News Korea
- Seoul extends sales tax incentive for cars, packages small biz relief fund with extra tax - Pulse by Maeil Business News Korea
- Kimchi Day this year celebrates record-breaking exports - Pulse by Maeil Business News Korea
- Korea’s oldest lead-acid battery maker Sebang to ship out EV battery packs from March - Pulse by Maeil Business News Korea
- Oldest luxury shopping mall MustIt rides on frenzy over luxury by young Koreans - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 넥스트 엔비디아는 어디
- “영원할 줄 알았는데”…지연♥황재균, “이혼설로 대중 충격” - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이